Enterprise Value

113.2M

Cash

108.3M

Avg Qtr Burn

-25.98M

Short % of Float

10.01%

Insider Ownership

1.44%

Institutional Own.

83.35%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tamibarotene (SY-1425) (RARα agonist) Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Big Mover™

Susp. Mover™

Phase 3

Data readout

Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin Details
Acute myeloid leukemia, Cancer

Big Mover™

Susp. Mover™

Phase 2

Data readout

Failed

Discontinued

SM-88 Details
Sarcoma, Bone cancer, Breast cancer

Failed

Discontinued

Failed

Discontinued

SM-88 Details
Pancreatic cancer

Failed

Discontinued

SM-88 Details
Prostate cancer, Prostate disease

Failed

Discontinued

SM-88 Details
Bone cancer, Sarcoma

Failed

Discontinued

Failed

Discontinued